title: The intergroup/RTOG 85-01 concurrent chemoradiation regimen for Japanese esophageal cancer.
abstract: OBJECTIVE
  To evaluate outcome of the U.S. RTOG/Intergroup Protocol 85-01 for 44 Japanese esophageal cancer patients.
  
  
  METHODS
  Between 1996 and 2004, patients with esophageal cancer received the Intergroup concurrent chemoradiation therapy regimen for the primary treatment (n=44, group A). We compared the data with those of patients receiving radiotherapy (RT) combined with the weekly chemotherapy regimen (n=12, group B) and with those of patients receiving RT combined with the daily low-dose chemotherapy regimen (n=24, group C).
  
  
  RESULTS
  The median survival period was 14.9 months in group A, 5.7 months in group B, and 6.3 months in group C. The survival rates at 1 and 3 years were 56% and 26% in group A, 42% and 21% in group B (p=0.3307), and 27% and 18% in group C (p=0.0462), respectively.
  
  
  CONCLUSIONS
  The prognosis of patients who received the Intergroup regimen for esophageal cancer was significantly better than that of patients who received the daily low-dose chemotherapy regimen. The Intergroup regimen is well tolerable for the Japanese patients too.
authors.affiliation: Department of Radiology, University of Tokyo Hospital, Tokyo, Japan. yamashitah-RAD@h.u-tokyo.ac.jp
authors.forename: Hideomi
authors.initials: H
authors.lastname: Yamashita
authors.forename: Keiichi
authors.initials: K
authors.lastname: Nakagawa
authors.forename: Masao
authors.initials: M
authors.lastname: Tago
authors.forename: Naoki
authors.initials: N
authors.lastname: Nakamura
authors.forename: Kenshiro
authors.initials: K
authors.lastname: Shiraishi
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Mafune
authors.forename: Michio
authors.initials: M
authors.lastname: Kaminishi
authors.forename: Kuni
authors.initials: K
authors.lastname: Ohtomo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D024221:Antineoplastic Protocols; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011882:Radiotherapy, High-Energy; D016019:Survival Analysis; D014481:United States